MITOMYCIN-C, BLEOMYCIN, VINCRISTINE, AND CIS-PLATINUM IN THE TREATMENT OF ADVANCED, RECURRENT SQUAMOUS-CELL CARCINOMA OF THE CERVIX

  • 1 January 1981
    • journal article
    • research article
    • Vol. 4  (3) , 313-316
Abstract
A combination chemotherapy regimen containing mitomycin C (10 mg/m2, day 2), vincristine (0.5 mg/m2, day 1 and 4), bleomycin (30 U QD [every day], days 1-4 as a continuous i.v. infusion during courses 1 and 2 only) and cis-platinum (50 mg/m2, days 1 and 22) was administered every 6 wk to 14 evaluable patients with advanced (i.e., Stage IVB) and/or recurrent squamous cell carcinoma of the cervix. Four patients (29%) achieved a complete response, lasting 8, 9.5+, 17+ and 21+ mo. Three of these patients have had complete disappearance of their pulmonary metastases; 1 has had resolution of a large left-sided pelvic wall mass. Two additional patients (14%) had a partial response to therapy, each lasting 1.5 mo. The median survival for these 14 patients was 9.0 mo. The chemotherapy regimen was well tolerated. There were no drug-related deaths and no instances of severe or irreversible renal dysfunction or peripheral neuropathy. The mean lowest white blood cell and platelet counts were 4540 and 205,000/mm3, respectively. Although severe or life-threatening thrombocytopenia occurred in only 36% patients, it appeared to be the dose-limiting toxicity of this drug combination.